Jaguar Health (NASDAQ:JAGX) Upgraded by StockNews.com to Hold

Posted by Patrick Bannon on Sep 14th, 2024

StockNews.com upgraded shares of Jaguar Health (NASDAQ:JAGX – Free Report) from a sell rating to a hold rating in a research note issued to investors on Friday morning.

Jaguar Health Stock Down 0.9 %

Shares of NASDAQ JAGX opened at $1.10 on Friday. Jaguar Health has a 1-year low of $0.95 and a 1-year high of $31.74. The company has a debt-to-equity ratio of 1.32, a current ratio of 2.10 and a quick ratio of 1.60. The business’s 50 day moving average is $1.83 and its two-hundred day moving average is $5.25.

Jaguar Health (NASDAQ:JAGX – Get Free Report) last announced its earnings results on Tuesday, August 13th. The biotechnology company reported ($4.04) EPS for the quarter, missing analysts’ consensus estimates of ($1.20) by ($2.84). Jaguar Health had a negative return on equity of 412.63% and a negative net margin of 350.18%. The company had revenue of $2.72 million during the quarter. As a group, analysts anticipate that Jaguar Health will post -0.78 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Jaguar Health

An institutional investor recently bought a new position in Jaguar Health stock. Perritt Capital Management Inc purchased a new position in shares of Jaguar Health, Inc. (NASDAQ:JAGX – Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 25,000 shares of the biotechnology company’s stock, valued at approximately $90,000. Perritt Capital Management Inc owned about 0.51% of Jaguar Health as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 12.04% of the company’s stock.

Jaguar Health Company Profile

(Get Free Report)

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.